Sanofi SA (SNY)
47.98
+0.20
(+0.42%)
USD |
NASDAQ |
Nov 21, 16:00
47.98
0.00 (0.00%)
After-Hours: 17:06
Price Chart
Key Stats
| Price and Performance | |
|---|---|
| Market Cap | 120.29B |
| 52 Week High (Daily) | Upgrade |
| 52 Week Low (Daily) | Upgrade |
| All-Time High (Daily) | Upgrade |
| Year to Date Total Returns (Daily) | Upgrade |
| 1 Month Total Returns (Daily) | Upgrade |
| 1 Year Total Returns (Daily) | 7.05% |
| Valuation | |
| PE Ratio | 24.31 |
| PE Ratio (Forward) | Upgrade |
| PS Ratio | 2.265 |
| Price to Book Value | 1.544 |
| EV to EBITDA | Upgrade |
| Dividend | |
|---|---|
| Dividend | 2.037 |
| Dividend Yield (Forward) | Upgrade |
| Financials | |
| Revenue (5 Year Growth) | Upgrade |
| Revenue (Quarterly YoY Growth) | Upgrade |
| EPS Diluted (5 Year Growth) | Upgrade |
| EPS Diluted (Quarterly YoY Growth) | Upgrade |
| Debt to Equity Ratio | -- |
| Return on Equity | Upgrade |
| Return on Assets | Upgrade |
| Risk | |
| Beta (5Y) | Upgrade |
| Max Drawdown (5Y) | 33.52% |
Profile
| Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, over-the-counter treatments and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 20% of total sales, but profits are shared with Regeneron. Just over 40% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue. |
| URL | https://www.sanofi.com |
| Investor Relations URL | https://www.sanofi.com/en/investors |
| HQ State/Province | N/A |
| Sector | Health Care |
| Industry | Pharmaceuticals |
| Equity Style | Large Cap/Blend |
| Next Earnings Release | Jan. 31, 2025 (est.) |
| Last Earnings Release | Oct. 25, 2024 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | May. 09, 2024 |
Ratings
Profile
| Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, over-the-counter treatments and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 20% of total sales, but profits are shared with Regeneron. Just over 40% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue. |
| URL | https://www.sanofi.com |
| Investor Relations URL | https://www.sanofi.com/en/investors |
| HQ State/Province | N/A |
| Sector | Health Care |
| Industry | Pharmaceuticals |
| Equity Style | Large Cap/Blend |
| Next Earnings Release | Jan. 31, 2025 (est.) |
| Last Earnings Release | Oct. 25, 2024 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | May. 09, 2024 |